**Shilpa Medicare Ltd.** is a global pharmaceutical company headquartered in Hyderabad, India. Founded in 1987, the company is primarily engaged in the development, manufacturing, and marketing of generic pharmaceutical products, active pharmaceutical ingredients (APIs), and biosimilars. Shilpa Medicare focuses on a wide range of therapeutic areas, including oncology, cardiology, neurology, and other specialized treatments.
The company has a strong presence in both the domestic and international markets, exporting its products to over 100 countries. With a commitment to quality and innovation, Shilpa Medicare invests heavily in research and development (R&D), striving to develop cost-effective solutions that improve patient outcomes. It has state-of-the-art manufacturing facilities that adhere to international regulatory standards, including those of the U.S. FDA, EU, and WHO-GMP.
Shilpa Medicare is known for its focus on biosimilars, with a robust pipeline of biosimilar products for various cancers and autoimmune diseases. Its efforts in cutting-edge research and manufacturing excellence have positioned it as a leading player in the global pharmaceutical industry.
